Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma
Research output: Contribution to journal › Journal article › Research › peer-review
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.
Original language | English |
---|---|
Journal | Drugs of the Future |
Volume | 46 |
Issue number | 7 |
Pages (from-to) | 529-536 |
ISSN | 0377-8282 |
DOIs | |
Publication status | Published - 2021 |
- Tezepelumab, AMG-157, MEDI-9929, TSLP, Asthma, Atopic dermatitis, Biologics, Pharmacokinetics, Clinical study, GENOME-WIDE ASSOCIATION, IGM(+) B-CELLS, UNCONTROLLED ASTHMA, IN-VITRO, PHARMACOKINETICS, DIFFERENTIATION, TOLERABILITY, PHENOTYPE, CYTOKINE, SAFETY
Research areas
ID: 274871668